Stanley C. Erck - Mar 10, 2022 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
President and CEO, Director
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Mar 10, 2022
Transactions value $
$0
Form type
4
Date filed
3/14/2022, 07:43 PM
Previous filing
Dec 16, 2021
Next filing
Jul 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Stock Option (Right to Buy) Award $0 +62.2K $0.00 62.2K Mar 10, 2022 Common Stock 62.2K $77.77 Direct F1
transaction NVAX Restricted Stock Units Award $0 +41.5K $0.00 41.5K Mar 10, 2022 Common Stock 41.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the March 10, 2022 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date.